Hutchinson Center researchers and Duke University colleagues discover a genomic signature that may allow doctors to individualize therapy for men with metastatic prostate cancer
March 23, 2009
Fred Hutchinson Cancer Research Center researchers Drs. Elahe Mostaghel and Peter Nelson and colleagues at Duke University’s Institute for Genome Sciences & Policy authored a paper announcing the discovery of a genomic signature that may ultimately allow doctors to individualize therapy for men with aggressive prostate cancer that has metastasized to other organs.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.